Studies have demonstrated that combining PD1/PD-L1 inhibitors with chemotherapeutic agents like fluoropyrimidine, oxaliplatin, and irinotecan improves immune recognition by upregulating MHC-I expression and reducing tumor-associated immunosuppressive cells, such as MDSCs and Tregs. The gene discussed is CD274; the disease is neoplasm.